Access Program Information
<p>This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of <strong>afatinib</strong> in advanced <strong>NSCLC patients</strong> who harbor an <strong>EGFR mutation</strong>.</p>